ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CLYM / insiders
ACRS (19) IRWD (59) NVCT (37) GERN (28) ⌘ Pro Terminal →

Climb Bio Inc. (CLYM) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$9.74 -4.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.63

Climb Bio Inc. (CLYM) carries a Roarable Rating of E (Strong Sell) with 28/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $588.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CLYM Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CLYM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Climb Bio Inc. (NASDAQ: CLYM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.74 (-4.98% 1D, market cap $588.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLYM ranks #856 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CLYM compare to ACRS and IRWD in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLYM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRS (Aclaris Therapeutics Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C- grade (59/100 RQD, P/E 24.9x, ROIC 85.0%, cap $578.3M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CLYM?
▼

Per CLYM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768446), Climb Bio Inc. generated $190.1M in revenue (-17.2% YoY), -$59.9M in net income, and -$54.5M in free cash flow against $167.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $9.63 (-1.09%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (28/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510028
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (4)Whales (6)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.4% Base Target
$19 Bull$8 Base$7 Bear
📬 FREE CLYM RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CLYM)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (28/100 Composite)
🔍 WHY CLYM SCORES 28/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (36% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+6/20 pts (21% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
36
Grade E$10.31+4.8% Next Q
Q2 (-2Q)
33
Grade E$10.80-11.4% Next Q
Q3 (-1Q)
31
Grade E$9.57+1.8% Next Q
Current
28
Grade E$9.74-10% Hist 90D α
Trajectory: E (36) → E (28)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CLYM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CLYM currently carries a cautious 28/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.34) and Max Pain ($10.23) forces dealer call-delta covering toward $19.25.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CLYM• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CLYM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 28%NO 72%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

CLYM Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (CLYM)

No recent open-market Form 4 cluster sales or emergency dumps flagged on CLYM. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CLYM)

  • ✓Walkthrough of CLYM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CLYM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +0.52%📐 HORIZONTAL RANGE
2026-11-03O $10.33H $10.33L $9.74C $9.74VOL 708.8K
RES: $22.15SUP: $8.42SMA50: $12.34SMA200: $10.44
$19.33$15.18$11.03$6.88$2.73RES $22.15SUP $8.42$9.742026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CLYM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CLYM Butterfly Map → + Track CLYM →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CLYM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CLYM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CLYM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CLYM)

Health Care Rank #856 of 1016 ⚔️ ACRS vs CLYM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CLYM vs. ACRS, IRWD, NVCT, GERN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Climb Bio Inc. (CLYM) ranks #856 by composite RQD confidence (28/100, grade E) and #418 by equity capitalization ($588.7M). Within this direct 5-issuer industry benchmark cohort, IRWD leads on earnings valuation at 24.9x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with CLYM at 28/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CLYM ACTIVE
Climb Bio Inc.
E 28/100 — — -35.0% -4.98% $588.7M Benchmark Subject
ACRS
Aclaris Therapeutics Inc.
E 19/100 — 73.3% -35.0% -4.28% $584.4M /acrs-vs-clym →
IRWD
Ironwood Pharmaceuticals Inc. (Class A)
C- 59/100 24.9x — 85.0% -1.14% $578.3M /irwd-vs-clym →
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M /nvct-vs-clym →
GERN
Geron Corporation
E 28/100 — — -20.2% +3.88% $574.6M /gern-vs-clym →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001768446

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Climb Bio Inc. (CLYM) reported GAAP revenue of $190.1M (-17.2% vs. FY2024 revenue of $229.7M , and +68.5% cumulative change since FY2023) , GAAP net income of -$59.9M, operating cash flow of -$54.4M, and free cash flow of -$54.5M (-250.5% YoY). On the balance sheet, CLYM closed FY2025 with $167.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $190.1M -$59.9M -$54.4M -$54.5M $167.7M —
FY2024 (FY) 2024-12-31 $229.7M -$73.9M -$15.6M -$15.6M $217.2M —
FY2023 (FY) 2023-12-31 $112.8M -$35.1M -$20.6M -$20.6M — —

3. CLYM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CLYM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Climb Bio Inc. (NASDAQ: CLYM) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 28/100 at a spot price of $9.74 (-4.98% 1D, market cap $588.7M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 5/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CLYM ranks #856 in composite RQD confidence.

How does CLYM compare to ACRS and IRWD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CLYM carries a Roarable E (28/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACRS (Aclaris Therapeutics Inc.) holds a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $584.4M) and IRWD (Ironwood Pharmaceuticals Inc. (Class A)) posts a C- grade (59/100 RQD, P/E 24.9x, ROIC 85.0%, cap $578.3M). Among the 5-stock peer group, IRWD leads on earnings multiple (24.9x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CLYM?

Per CLYM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001768446), Climb Bio Inc. generated $190.1M in revenue (-17.2% YoY), -$59.9M in net income, and -$54.5M in free cash flow against $167.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CLYM trading relative to its 50-day, 200-day, and 52-week technical levels?

CLYM last traded at $9.74 (-4.98% on volume of 1,146,945 shares), positioning the stock -21.07% below its 50-day simple moving average ($12.34) and -6.70% below its 200-day simple moving average ($10.44). Across its 52-week range of $1.63 to $18.33, CLYM sits at the 48.6% percentile with a 14-day RSI of 44.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.52 to $10.96).

Direct Sub-Reports: CLYM RQD Cockpit CLYM 12M Forecast CLYM Earnings & Move CLYM Dividends & DRIP CLYM Insiders & 13F CLYM Whale Options CLYM Profit Sankey CLYM News & Why
ROARABLE RATING BRIEF • RQD 28/100 (E) ✓ SEC XBRL & RQD VERIFIED

CLYM — Climb Bio Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Climb Bio Inc. (CLYM) earns a live Roarable RQD composite score of 28/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $9.74 (-4.98% 1D, market capitalization $588.7M).

  • Fundamental Cash Engine (4/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -9.19%.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (10/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Climb Bio Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,. Reported revenue is — in each of the three listed fiscal years, indicating no reported revenue in the source period. The company's market capitalization is $0.6B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Climb Bio Inc. (CLYM) reported $190.1M in annual revenue (up from $229.7M in FY2024, -17.2% YoY) and -$59.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($112.8M revenue, -$35.1M net income) through FY2025, CLYM scaled operating cash flow to -$54.4M and free cash flow to -$54.5M, backed by $167.7M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 28/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -9.19% and institutional whale pillar of 6/20. With Fundamental Cash Engine at 4/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $1.63 – $18.33 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), CLYM carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can CLYM sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $190.1M and free cash flow of -$54.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CLYM's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CLYM Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Climb Bio Inc. (CLYM) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CLYM Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CLYM Bull vs. Bear Conversation Board — What's Your Call at $9.74?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CLYM 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CLYM:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $13.12 (+28.0%)
📌 Pinned Debate

Balance sheet and a cited Deutsche Bank Buy initiation on the autoimmune pipeline offer partial support against weak cash flows.

Picked up a starter position in CLYM in my $100K Virtual Cash book at $10.25. Balance sheet and a cited Deutsche Bank Buy initiation on the autoimmune pipeline offer partial support against weak cash flows.. Trading inside a $1.85–$18.33 52-week range with -9.19% FCF yield gives solid downside support if Biotechnology: Pharmaceutical Preparations multiples expand this quarter.

SectorRotator 🐂 BULL

@DeltaGamma_99 Agree on the RQD 28/100 quality, though with 1.0 beta I'm scaling in with half-size at $10.25 and keeping dry powder in case we test $9.53.

FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH 🎯 Target: $8.10 (-21.0%)
Spot @ $10.25

ROIC of -35%, FCF yield of -9.19%, and three consecutive years of operating losses leave the cash engine unproven.

ROIC of -35%, FCF yield of -9.19%, and three consecutive years of operating losses leave the cash engine unproven.. Look at the math on CLYM: paying current EV/EBITDA multiples for -35.0% ROIC and 0.0% operating margins leaves zero margin of safety if Biotechnology: Pharmaceutical Preparations demand softens. I'd wait for a retest of $9.02 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%